Literature DB >> 31062178

Bismuth Subsalicylate Coagulopathy in a Patient with Chronic Liver Disease.

Catherine Yu1, Noel Eustaquio2, Diane P Calello1,2, Bruce E Ruck2, Lewis S Nelson1,2, Cynthia Santos3,4.   

Abstract

Bismuth subsalicylate (BSS) is the active ingredient in over-the-counter antacid and antidiarrheal medications. Coagulopathy in the setting of acetylsalicylic acid toxicity is well documented but not in setting of bismuth subsalicylate overuse. We present a case report of coagulopathy from BSS poisoning in a patient with underlying cirrhosis. The patient's high prothrombin time suggests inhibition of vitamin K-dependent coagulation factors. The patient had decreased factor V activity, which is responsible for converting prothrombin to thrombin. Patients with cirrhosis often have hypoprothrombinemia which may be exacerbated by salicylate-induced coagulopathy. Given the widespread use of BSS products, physicians should recognize coagulopathy as a possible manifestation of toxicity especially in patients with underlying liver disease.

Entities:  

Keywords:  Bismuth; Coagulopathy; Liver disease; Salicylate

Mesh:

Substances:

Year:  2019        PMID: 31062178      PMCID: PMC6597674          DOI: 10.1007/s13181-019-00709-y

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  20 in total

1.  Blood coagulation at the site of microvascular injury: effects of low-dose aspirin.

Authors:  A Undas; K Brummel; J Musial; K G Mann; A Szczeklik
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

2.  The in vitro effect of N-acetylcysteine on prothrombin time in plasma samples from healthy subjects.

Authors:  Anthony F Pizon; David H Jang; Henry E Wang
Journal:  Acad Emerg Med       Date:  2011-04       Impact factor: 3.451

3.  Bleeding, salicylates, and prolonged prothrombin time: three case reports and a review of the literature.

Authors:  H G Goldsweig; M Kapusta; J Schwartz
Journal:  J Rheumatol       Date:  1976-03       Impact factor: 4.666

4.  Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard.

Authors:  A S Yip; W H Chow; Y T Tai; K L Cheung
Journal:  Postgrad Med J       Date:  1990-05       Impact factor: 2.401

Review 5.  Bismuth therapy in gastrointestinal diseases.

Authors:  S L Gorbach
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

6.  In vitro study of N-acetylcysteine on coagulation factors in plasma samples from healthy subjects.

Authors:  David H Jang; Matthew D Weaver; Anthony F Pizon
Journal:  J Med Toxicol       Date:  2013-03

Review 7.  Bismuth subsalicylate: history, chemistry, and safety.

Authors:  D W Bierer
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

Review 8.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

9.  Potentiation of warfarin anticoagulation associated with topical methyl salicylate.

Authors:  J D Joss; R F LeBlond
Journal:  Ann Pharmacother       Date:  2000-06       Impact factor: 3.154

10.  Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.

Authors:  Angela L Bingham; Rex O Brown; Roland N Dickerson
Journal:  Nutr Clin Pract       Date:  2013-10-25       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.